XL-388

XL-388
Identifiers
IUPAC name
  • [7-(6-aminopyridin-3-yl)-3,5-dihydro-2H-1,4-benzoxazepin-4-yl]-(3-fluoro-2-methyl-4-methylsulfonylphenyl)methanone
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC23H22FN3O4S
Molar mass455.50 g·mol−1
3D model (JSmol)
SMILES
  • CC1=C(C=CC(=C1F)S(=O)(=O)C)C(=O)N2CCOC3=C(C2)C=C(C=C3)C4=CN=C(C=C4)N
InChI
  • InChI=1S/C23H22FN3O4S/c1-14-18(5-7-20(22(14)24)32(2,29)30)23(28)27-9-10-31-19-6-3-15(11-17(19)13-27)16-4-8-21(25)26-12-16/h3-8,11-12H,9-10,13H2,1-2H3,(H2,25,26)
  • Key:LNFBAYSBVQBKFR-UHFFFAOYSA-N

XL-388 is a drug which acts as a potent and selective inhibitor of both subtypes of the mechanistic target of rapamycin (mTOR), mTORC1 and mTORC2.[1] It is being researched for the treatment of various forms of cancer,[2][3][4] and has also been used to demonstrate a potential application for mTOR inhibitors in the treatment of neuropathic pain.[5][6]

References

  1. Takeuchi CS, Kim BG, Blazey CM, Ma S, Johnson HW, Anand NK, et al. (March 2013). "Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR)". Journal of Medicinal Chemistry. 56 (6): 2218–34. doi:10.1021/jm3007933. PMID 23394126.
  2. Zhu YR, Zhou XZ, Zhu LQ, Yao C, Fang JF, Zhou F, et al. (August 2016). "The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models". Oncotarget. 7 (31): 49527–49538. doi:10.18632/oncotarget.10389. PMC 5226526. PMID 27385099.
  3. Xiong Z, Zang Y, Zhong S, Zou L, Wu Y, Liu S, et al. (May 2017). "The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent". Oncotarget. 8 (18): 30151–30161. doi:10.18632/oncotarget.15620. PMC 5444733. PMID 28404914.
  4. Zhong S, Xue J, Cao JJ, Sun B, Sun QF, Bian LG, et al. (November 2020). "The therapeutic value of XL388 in human glioma cells". Aging. 12 (22): 22550–22563. doi:10.18632/aging.103791. PMC 7746352. PMID 33159013.
  5. Choi S, Kim K, Cha M, Kim M, Lee BH (January 2020). "mTOR signaling intervention by Torin1 and XL388 in the insular cortex alleviates neuropathic pain". Neuroscience Letters. 718: 134742. doi:10.1016/j.neulet.2020.134742. PMID 31917234.
  6. Cha M, Choi S, Kim K, Lee BH (November 2020). "Manganese-enhanced MRI depicts a reduction in brain responses to nociception upon mTOR inhibition in chronic pain rats". Molecular Brain. 13 (1): 158. doi:10.1186/s13041-020-00687-1. PMC 7713325. PMID 33267907.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.